Join us at booth H7C19

Join us at booth H7C19
We are thrilled to announce the publication of a major clinical study conducted at MEDIAN Klinik Flechtingen, showcasing the benefits of ReOxy® for patients with long COVID.
We are thrilled to announce the publication of a major clinical study conducted at MEDIAN Klinik Flechtingen, showcasing the benefits of ReOxy® for patients with long COVID.
This year, Ai Mediq had the privilege of participating in the European Society of Cardiology (ESC) Congress held in the city of Amsterdam. This prestigious congress brings together experts from private and public institutions worldwide to exchange knowledge and discoveries in the realm of cardiovascular medicine.
Ai Mediq is looking forward to Arab Health 2023. Traditionally, we will be there together with delegation of Ministry of Economy at the joint booth Z1.B50.
Ai Mediq was happy to be one of the seventeen Luxembourg companies presented during IHI Kick-off and brokerage event that took place on June 14, 2022 in Brussels, Belgium.
The results of the application of ReOxy therapy in patients with osteoarthritis and post-covid syndrome has been demonstrated during the presentation at Eular22
Ai Mediq is publishing a translation of publication by Prof. Oleg S. Glazachev for RBC.RU regarding the implications of COVID-19 and therapeutic potential of application of ReOxy device to rehabilitate the patients.
Presentation of the Intermittent Hypoxic Training Method in one of the well-known Liliane Goschy-FRITZ Institute in Baden-Baden, Germany on the 15th if July 2020.
Currently, all efforts are focused on patients with acute diseases. All hospitals are crowded with severe patients with COVID-19 who need emergency care to save their lives.